Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2015Journal of Medicinal ChemistryOpen Access

The Discovery of Macrocyclic XIAP Antagonists from a DNA-Programmed Chemistry Library, and Their Optimization To Give Lead Compounds with in Vivo Antitumor Activity

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBenjamin A. SeigalEnsemble Therapeutics (United States)WCWilliam H. ConnorsEnsemble Therapeutics (United States)AFAndrew W. FraleyBoston College

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Seigal et al. (2015) studied this question.

synapsesocial.com/papers/6a7ee2d60d7a2a64b34f77d1https://doi.org/10.1021/jm501892g
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)2013 · 117 citations
  2. 2IAP family proteins---suppressors of apoptosis1999 · 2,562 citations
  3. 3Design, Synthesis, and Characterization of a Potent, Nonpeptide, Cell-Permeable, Bivalent Smac Mimetic That Concurrently Targets Both the BIR2 and BIR3 Domains in XIAP2007 · 207 citations
  4. 4Inhibitor of apoptosis proteins and apoptosis2008 · 122 citations
  5. 5A Potent Bivalent Smac Mimetic (SM-1200) Achieving Rapid, Complete, and Durable Tumor Regression in Mice2013 · 35 citations